Best of ASCO - 2014 Annual Meeting

 

Welcome

Biomarkers and Correlative Studies from Immunotherapy Trials

Developmental Therapeutics—Immunotherapy

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Anatomic site of metastases can influence response to nivolumab in NSCLC patients.

Andrea Botticelli

e15021

Application of NCCN guidelines in PD-L1 expression for patients with stage IV non-small cell lung cancer.

Ilana Schlam

e15030

Association of increased T cell infiltrates in the invasive margin with relapse-free survival in patients with cholangiocarcinoma (CCA).

Petra Prins

e15001

Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.

Vicki Leigh Keedy

3031

CD8 and PD-L1 determination in lung tumor tissue as prognostic biomarker and a predictive marker of anti PD-1 efficacy.

Jean-David Fumet

3021

Changes of microbiome profile during nivolumab treatment in NSCLC patients.

Andrea Botticelli

e15020

Combination immunotherapy selection for PD-1 axis driven tumors.

Sarabjot Pabla

e15024

Combination of lactate dehydrogenase and tumor mutational burden to predict clinical benefit of anti-CTLA-4 therapy in melanoma.

Wenjing Xiao

e15029

Co-mutations of DNA damage response system as predictive biomarker for immune checkpoint blockades.

Zhijie Wang

3024

Deep sequencing of the t-cell receptors for monitoring peripheral CD8+T cells in advanced NSCLC Chinese patients treated with anti-PD-L1 antibody.

Jin Sheng

e15025

Demonstration of anti-tumor immunity via intratumoral regulated platform ad-RTS-hIL-12 in advanced breast cancer and recurrent glioblastoma patients.

Francois M. Lebel

3038

Determination of tumor mutational burden using FFPE material: Content and performance comparison of different gene panels.

Volker Endris

e15010

Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).

Dylan J. Martini

e15022

Early reduction in circulating tumor DNA (ctDNA) and survival in gastric cancer patients (pts) treated with durvalumab (D), tremelimumab (T), or durvalumab in combination with tremelimumab (D+T).

Philip Z. Brohawn

e15027

Early trends of ctDNA levels in non-small cell lung cancer patients treated with immunotherapy (CLIP-IT): Pilot study.

Meera Yogarajah

e15014

Evaluating the link between T cell receptor beta variable gene polymorphism and immune mediated adverse events during checkpoint blockade immunotherapy.

Timothy Looney

e15002

Exploration of baseline derived neutrophil to lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors (ICI) or cytotoxic chemotherapy (CCT).

Dickran Garo Kazandjian

3035

First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.

Ravit Geva

3029

Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors.

Natalie Vokes

3036

Germinal immunogenetics as a predictor of anti-PD1/PD-L1 treatment outcome.

Gerard A. Milano

3034

Host-microbe interactions mediating antitumorigenic effects of MRX0518, a gut microbiota-derived bacterial strain, in breast, renal and lung carcinoma.

Alex Stevenson

e15006

Human leukocyte antigen (HLA) B44 supertype and immunotherapy outcomes in non-small cell lung cancer (NSCLC).

Henry Lu

3026

Impact on immune effectors of anti-tumor antibodies isolated from cancer patients.

Amy Manning-Bog

e15015

Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials.

Ignacio Matos

3032

Medical image computing to assess tumor infiltrating CD8 T cells, tumor immune phenotype and response to anti-PD-1/PD-L1 immunotherapy in prospective phase 1 trials.

Roger Sun

3016

Mismatch repair deficiency testing for immune checkpoint therapy: Immunohistochemistry vs microsatellite instability.

Sucha Sudarsanam

3022

Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications.

Michael Carleton

3020

Phase 1, open-label, adaptive biomarker trial that informs the evolution of combination immuno-oncology (IO) therapies (ADVISE), a precision IO approach to personalized medicine.

Jason J. Luke

TPS3101

Pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.

Craig L. Slingluff

3033

Relationship between checkpoint molecule B7-H3 and refractoriness to anti-PD-1 therapy in non-small cell lung cancer.

Kimio Yonesaka

3023

Safety, tolerability and outcomes of immunotherapy in minority underserved population.

Ahmed T Ahmed

e15004

Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy.

Michael Carleton

3025

Somatic STK11/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC.

Maria Jure-Kunkel

3028

The sharing of T cell clones in peripheral CD8+PD-1+ T cells with TILs is a novel biomarker predicting the efficacy of anti-PD-L1 therapy.

Jie-Fei Han

e15007

Underlying host immune dysregulation in cancer patients developing immune-related adverse events.

David E. Gerber

3030

Use of cell-free circulating RNA (cfRNA) levels in plasma and expression of HER2 and PD-L1 to monitor disease status in metastatic cancer patients.

Luis E. Raez

e15013

Using target capture sequencing detect microsatellite instability(MSI), tumor mutational burden(TMB) and POLE/POLD1 mutations in colorectal cancer.

Jing Wang

e15012